KRAS and non-small cell lung carcinoma: Regarding PDL1 expression, one analysis (N = 282) showed that, in KRAS-mutant NSCLC, the efficacy of ICIs was higher, even though this was not statistically significant for patients with a PD-L1 expression >1% vs. <1%.